scholarly journals Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy

2016 ◽  
Vol 12 (6) ◽  
pp. 5370-5376 ◽  
Author(s):  
Shan Li ◽  
Ting-Ting Feng ◽  
Yang Guo ◽  
Xianjun Yu ◽  
Qiuyue Huang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Protein Phosphatase ◽  
Triple Negative ◽  
Protein Phosphatase 2A ◽  
Tumor Survival ◽  
Phosphatase 2A

scholarly journals Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Katsunori Tozuka ◽  
Pattama Wongsirisin ◽  
Shigenori E. Nagai ◽  
Yasuhito Kobayashi ◽  
Miki Kanno ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Protein Phosphatase ◽  
Protein Phosphatase 2A ◽  
Recurrent Breast Cancer ◽  
Stage I ◽  
Breast Cancer Patients ◽  
Potential Biomarker ◽  
Phosphatase 2A ◽  
Mcf 7

AbstractTo understand the mechanism underlying metastasis, identification of a mechanism-based and common biomarker for circulating tumour cells (CTCs) in heterogenous breast cancer is needed. SET, an endogenous inhibitor of protein phosphatase 2A, was overexpressed in all subtypes of invasive breast carcinoma tissues. Treatment with SET-targeted siRNAs reduced the motility of MCF-7 and MDA-MB-231 cells in transwell assay. SET knockdown reduced the number of mammospheres by 60–70% in MCF-7 and MDA-MB-231 cells, which was associated with the downregulation of OCT4 and SLUG. Hence, we analysed the presence of SET-expressing CTCs (SET-CTCs) in 24 breast cancer patients. CTCs were enriched using a size-based method and then immunocytochemically analysed using an anti-SET antibody. SET-CTCs were detected in 6/6 (100%) patients with recurrent breast cancer with a median value of 12 (12 cells/3 mL blood), and in 13/18 (72.2%) patients with stage I–III breast cancer with a median value of 2.5, while the median value of healthy controls was 0. Importantly, high numbers of SET-CTCs were correlated with lymph node metastasis in patients with stage I–III disease. Our results indicate that SET contributes to breast cancer progression and can act as a potential biomarker of CTCs for the detection of metastasis.

scholarly journals Differential expression of protein phosphatase 2A activator in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Protein Phosphatase ◽  
Protein Phosphatase 2A ◽  
Normal Breast ◽  
Recurrence Free Survival ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Free Survival ◽  
Phosphatase 2A

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding protein phosphatase 2A activator, PPP2R4, also known as PTPA (protein phosphatase 2 phosphatase activator) when comparing primary tumors of the breast to the tissue of origin, the normal breast. PPP2R4 mRNA was present at significantly higher quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of PPP2R4 in primary tumors of the breast was correlated with recurrence-free survival in patients with basal and luminal B type cancers, but in a contrary manner, demonstrating a complex relationship between correlation of primary tumor expression with recurrence-free survival based on molecular subtype. PPP2R4 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

scholarly journals Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer

2011 ◽  
Vol 32 (11) ◽  
pp. 644-651 ◽  
Author(s):  
Christopher H. Switzer ◽  
Sharon A. Glynn ◽  
Lisa A. Ridnour ◽  
Robert Y.-S. Cheng ◽  
Michael P. Vitek ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Nitric Oxide ◽  
Protein Phosphatase ◽  
Protein Phosphatase 2A ◽  
Phosphatase 2A ◽  
Novel Therapeutic

From mammalian development to breast cancer: All roads lead to Protein Phosphatase 2A

2018 ◽  
Vol 92 ◽  
pp. S127-S128
Author(s):  
N. Panicker ◽  
S. Roselli ◽  
R. Kahl ◽  
A. Mannan ◽  
L. Watt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Protein Phosphatase ◽  
Protein Phosphatase 2A ◽  
Mammalian Development ◽  
Phosphatase 2A

scholarly journals Deregulation of Protein Phosphatase 2A inhibitor SET is Associated with Malignant Progression in Breast Cancer

2021 ◽  
Author(s):  
Katsunori Tozuka ◽  
Pattama Wongsirisin ◽  
Shigenori E Nagai ◽  
Yasuhito Kobayashi ◽  
Miki Kanno ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Protein Phosphatase ◽  
Protein Phosphatase 2A ◽  
Recurrent Breast Cancer ◽  
Stage I ◽  
Breast Cancer Patients ◽  
Potential Biomarker ◽  
Phosphatase 2A ◽  
Mcf 7

Abstract To understand the mechanism underlying metastasis, identification of a mechanism-based and common biomarker for circulating tumour cells (CTCs) in heterogenous breast cancer is needed. SET, an endogenous inhibitor of protein phosphatase 2A, was overexpressed in all subtypes of invasive breast carcinoma tissues. Treatment with SET-targeted siRNAs reduced the motility of MCF-7 and MDA-MB-231 cells in transwell assay. SET knockdown reduced the number of mammospheres by 60-70% in MCF-7 and MDA-MB-231 cells, which was associated with the downregulation of OCT4 and SLUG. Hence, we analysed the presence of SET-expressing CTCs (SET-CTCs) in 24 breast cancer patients. CTCs were enriched using a size-based method and then immunocytochemically analysed using an anti-SET antibody. SET-CTCs were detected in 6/6 (100%) patients with recurrent breast cancer with a median value of 12 (12 cells/3 mL blood), and in 13/18 (72.2%) patients with stage I–III breast cancer with a median value of 2.5, while the median value of healthy controls was 0. Importantly, high numbers of SET-CTCs were correlated with lymph node metastasis in patients with stage I–III disease. Our results indicate that SET contributes to breast cancer progression and can act as a potential biomarker of CTCs for the detection of metastasis.

Sign in / Sign up

Export Citation Format

Share Document